# BillionToOne Inc. (BLLN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $99.39, market value $4.7 billion.

## Valuation
- **P/E (trailing): 138.0×** (5-yr avg 584.6×, 3-yr avg 584.6×). BillionToOne Inc. trades at 138.0× trailing earnings, well below its own five-year average of 584.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 66.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.65**. A PEG of 0.65 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 11.8×**. Each dollar of revenue is priced at 11.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 8.7×**. The shares trade at 8.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 84.7×**. Enterprise value is 84.7× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 0.3%** (5-yr avg 0.9%). Free cash flow equals 0.3% of the market value, below its five-year average of 0.9%, so the shares are pricier on cash than usual.
- **Earnings yield: 0.7%**. The inverse of the P/E: 0.7% of the price is earned each year.

## Profitability
- **Gross margin: 71.3%**. BillionToOne Inc. keeps 71.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 10.9%**. 10.9% of revenue is left after running the business.
- **Net margin: 2.4%**. 2.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 1.6%**. 1.6% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 82.7%**. Return on all capital, debt included, is 82.7%: comfortably above what that capital costs.
- **Return on assets: 6.0%**. Each dollar of assets produces 6.0% of profit.

## Growth
- **Revenue growth (1 yr): 100.0%**. Revenue grew 100.0% over the last year.
- **EPS growth (1 yr): 103.4%**. Earnings per share rose 103.4%, roughly in step with revenue.

## Financial health
- **Debt to equity: 0.12**. Debt is 0.12 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BillionToOne Inc. holds more cash than debt.
- **Altman Z-score: 20.07**. A Z-score of 20.07 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BillionToOne Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover BillionToOne Inc.; the consensus is buy, with an average price target of $119.71 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -33.9%** (60.4% above the low). Trading 34% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 1.78** (volatility 92%). Beta of 1.78 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BLLN · Page: https://foliofundamentals.com/stocks/blln

Not investment advice.